• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Galectin-3 inhibitors: a patent review (2008–present)

    Author(s)
    Blanchard, Helen
    Yu, Xing
    Collins, Patrick Michael
    Bum-Erdene, Khuchtumur
    Griffith University Author(s)
    Collins, Patrick
    Blanchard, Helen
    Yu, Xing
    Bum-Erdene, KB
    Year published
    2014
    Metadata
    Show full item record
    Abstract
    Introduction: Galectin-3 (Gal-3), a lectin with preference for ߭galactoside-containing carbohydrates, is a structurally unique member of the galectin family. It is ubiquitously expressed in various mammalian tissues with a wide distribution from the intracellular environment to the extracellular space. Gal-3 is a well-established player in numerous diseases, from infections to heart failure. Notably, as Gal-3 overexpression is associated with cancer drug resistance, it has been identified as a valuable therapeutic target in the fight against cancers. Areas covered: This review discusses the recent progress of patent ...
    View more >
    Introduction: Galectin-3 (Gal-3), a lectin with preference for ߭galactoside-containing carbohydrates, is a structurally unique member of the galectin family. It is ubiquitously expressed in various mammalian tissues with a wide distribution from the intracellular environment to the extracellular space. Gal-3 is a well-established player in numerous diseases, from infections to heart failure. Notably, as Gal-3 overexpression is associated with cancer drug resistance, it has been identified as a valuable therapeutic target in the fight against cancers. Areas covered: This review discusses the recent progress of patent applications (2008-present) and the current knowledge of pertinent Gal-3-inhibitor interactions in an effort to progress the development of selective and high affinity carbohydrate-based inhibitors targeting Gal-3, with an emphasis on engaging a structure-based drug design rationale. Expert opinions: The lack of commercially available anti-Gal-3 therapeutic reagents and its clear involvement in serious disease, notably cancer, leads to an urgent need for development of inhibitors that specifically target Gal-3. Design of potent and selective inhibitors targeting Gal-3 is challenging due to its weak protein-carbohydrate interactions along with the high sequence homology in the carbohydrate binding site region amongst galectins. To date, some chemical scaffolds have been exploited for design of promising effective Gal-3 inhibitors for cancer therapy.
    View less >
    Journal Title
    Expert Opinion in Therapeutic Patents
    Volume
    24
    Issue
    10
    DOI
    https://doi.org/10.1517/13543776.2014.947961
    Subject
    Structural Biology (incl. Macromolecular Modelling)
    Biomedical Engineering
    Pharmacology and Pharmaceutical Sciences
    Publication URI
    http://hdl.handle.net/10072/64143
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander